Pharmaceuticals
Sanofi and Regeneron announce a $1 billion expansion of their immunology alliance to develop next-generation antibodies, signaling confidence in type 2 inflammation biology despite upcoming Dupixent patent expiration.
Pharmaceuticals
A patient death and a trial amendment in Bristol Myers' Phase 3 admilparant program are raising fresh questions about liver toxicity in the LPA1R inhibitor class, just months before a pivotal readout that could reshape the IPF treatment landscape.
Biotechnology
Viking Therapeutics' VK2735 maintenance dosing data reveal a potential game-changer: patients can maintain 90-97% of weight loss on monthly injections instead of weekly ones. Here's what it means for the obesity drug market.
Pharmaceuticals
Eli Lilly's FDA approval of Onswik, a once-weekly basal insulin, marks a significant shift in diabetes management and intensifies competition with Novo Nordisk in the insulin market.
Pharmaceuticals
The FDA's approval of AbbVie's Juvmo marks the first selective D1/D5 dopamine receptor agonist for Parkinson's disease, introducing a genuinely new mechanism to a field that has relied on the same pharmacological approach for over 50 years.
Biotechnology
Celldex's barzolvolimab met all primary and secondary endpoints in Phase 3 CSU trials, demonstrating complete responses in 42-46% of patients at Week 12 and 45-54% by Week 24—establishing mast cell depletion as a genuine advance in chronic spontaneous urticaria treatment.
Biotechnology
Celldex's barzolvolimab Phase 3 data show complete response rates of 42-54% in chronic spontaneous urticaria, including patients who failed omalizumab. Here is what the mechanism means and why it matters.
Biotechnology
Alkermes' Phase 1b data for ALKS 7290, an orexin 2 receptor agonist, demonstrates the first clinical evidence that a new mechanism could transform ADHD treatment beyond traditional stimulants.
Biotechnology
On September 17, 2026, the FDA approved Fayuvi, the first treatment for Sanfilippo syndrome Type A—at a price of $3.95 million. What does this approval mean for rare disease medicine, access, and the future of gene therapy?
Pharmaceuticals
The FDA's approval of Kerendia for type 1 diabetes-associated kidney disease marks the first new treatment option in over 30 years for this underserved patient population.
Biotechnology
Vera Therapeutics' ORIGIN 3 Phase 3 trial demonstrates that TRUTAKNA met all prespecified endpoints, achieving eGFR stabilization and a 76% reduction in kidney disease progression risk in IgA nephropathy patients.
Pharmaceuticals
Novo Nordisk has rebranded as simply 'Novo.' The name change is the most visible signal yet that the company understands the urgency of its competitive challenge against Eli Lilly in the GLP-1 obesity drug market.